MD Conference Express - ENDO 2015 - (Page 10)
ClINICAl TrIAl HIGHlIGHTS
24 had no clinically significant effect on liver function
tests, which included aspartate aminotransferase, alanine
aminotransferase, total bilirubin, γ-glutamyltransferase,
alkaline phosphatase, and albumin.
This PK/PD analysis found an approximately doseproportional relationship for pasireotide LAR doseexposure over the 40- to 60-mg range that was evaluated.
Efficacy end points of GH and IGF-1 suppression had
a positive relationship with pasireotide exposure, with
greater response rates at the higher dose of 60 mg.
Biochemical Control of Acromegaly
Continued in PAOLA Trial Extension
Written by Kathy Boltz, PhD
Monica R. Gadelha, MD, Hospital Universitário
Clementino Fraga Filho, Universidade Federal do Rio de
Janeiro, Rio de Janeiro, Brazil, presented a preliminary
analysis of the phase 3 PAOLA study [NCT01137682] that
showed that biochemical control continued through
extension week 28. The intent within this extension
phase was to assess pasireotide long-acting release
(LAR) in patients with acromegaly over an extended
period of time.
Dr Gadelha and colleagues examined data through
extension week 28 of the extension phase of the 24-week,
randomized, phase 3 PAOLA study, which enrolled
patients with inadequately controlled acromegaly
[Gadelha MR et al. Lancet Diabetes Endocrinol. 2014].
The 24-week, phase 3 study had found that biochemical control, defined as growth hormone < 2.5 µg/L and
normalized insulinlike growth factor 1 (IGF-1), was
achieved by significantly more patients who received
pasireotide LAR 40 mg (15%; n = 10/65; P = .0006) or
60 mg (20%; n = 13/65; P < .0001) than those who received
octreotide LAR or lanreotide Autogel (0%; n = 0/68). The
most common adverse events in the phase 3 trial were
hyperglycemia, diabetes, and diarrhea. Serious adverse
events were reported in 6 patients receiving pasireotide
40 mg, 2 receiving pasireotide 60 mg, and 3 in the active
control group.
The patients who were in the control group continued
to receive the same doses in the extension phase from
week 24 through a 4-week bridging phase. Next, patients
from the control group who were not biochemically controlled received open-label pasireotide LAR 40 mg, and
their dose was increased to 60 mg if their disease became
uncontrolled. These were the crossover group.
The patients who were not in the control group
remained on pasireotide LAR at 40 or 60 mg during
the 4-week bridging phase. If they had not achieved
10
May 2015
biochemical control, they received open-label pasireotide
LAR 60 mg beginning at extension week 4. These patients,
the treatment groups, received a total of 52 weeks of treatment with pasireotide LAR for this analysis.
At extension week 28, biochemical control was
achieved by 18% of the patients in the pasireotide LAR
40-mg group (n = 9/49; 95% CI, 9 to 32) and by 33% in the
pasireotide LAR 60-mg group (n = 15/45; 95% CI, 20 to
49). Among the crossover group, 20% achieved biochemical control (n = 10/50; 95% CI, 10 to 34).
All 3 groups had a drop in IGF-1 levels during the
extension time. At week 28, normal IGF-1 was obtained
in 33% of the patients receiving pasireotide LAR 40 mg, in
38% receiving pasireotide LAR 60 mg, and in 24% of the
crossover group. Growth hormone levels of < 2.5 µg/L
were achieved by 39% of the patients receiving pasireotide LAR 40 mg, 47% of those receiving pasireotide LAR
60 mg, and 42% of the crossover group.
The safety profile was very similar to that of the core
study. This longer-term treatment identified no new
treatment-emergent safety signals.
Pasireotide may be a viable, long-term treatment
option for patients with acromegaly that is inadequately
controlled with first-generation somatostatin analogues.
Early Initiation of Low-Dose
Levothyroxine After Radioactive
Iodine Appears Safe
Written by Kathy Boltz, PhD
Spyridoula Maraka, MD, Mayo Clinic, Rochester,
Minnesota, USA, reported on results from an interim
safety analysis, which found that initiating low-dose
levothyroxine at 4 weeks after patients received radioactive iodine (RAI) for Graves' disease (GD) appears safe
and shows no increased incidence of hyperthyroidism.
Most patients with GD are treated with RAI and
reevaluated 2 to 3 months later; the majority are hypothyroid by that time, and some have related troublesome
symptoms and possible development or worsening of
Graves' orbitopathy.
This randomized double-blind controlled trial
[NCT01950260] was designed to determine whether early
treatment with levothyroxine after RAI therapy for GD
would prevent overt hypothyroidism. This interim analysis for safety was performed after the first 17 patients were
enrolled, with 11 patients receiving levothyroxine, 25 µg
QD, and 6 receiving placebo in a single tablet at 4 weeks
after RAI therapy. At 6 weeks after RAI therapy, the levothyroxine dose was increased to 50 µg QD and the placebo to 2 tablets per day. At 8 weeks after RAI therapy, the
www.mdce.sagepub.com
http://mdce.sagepub.com
Table of Contents for the Digital Edition of MD Conference Express - ENDO 2015
Contents
MD Conference Express - ENDO 2015
MD Conference Express - ENDO 2015 - (Page Cover1)
MD Conference Express - ENDO 2015 - (Page Cover2)
MD Conference Express - ENDO 2015 - (Page i)
MD Conference Express - ENDO 2015 - (Page ii)
MD Conference Express - ENDO 2015 - Contents (Page 1)
MD Conference Express - ENDO 2015 - Contents (Page 2)
MD Conference Express - ENDO 2015 - Contents (Page 3)
MD Conference Express - ENDO 2015 - Contents (Page 4)
MD Conference Express - ENDO 2015 - Contents (Page 5)
MD Conference Express - ENDO 2015 - Contents (Page 6)
MD Conference Express - ENDO 2015 - Contents (Page 7)
MD Conference Express - ENDO 2015 - Contents (Page 8)
MD Conference Express - ENDO 2015 - Contents (Page 9)
MD Conference Express - ENDO 2015 - Contents (Page 10)
MD Conference Express - ENDO 2015 - Contents (Page 11)
MD Conference Express - ENDO 2015 - Contents (Page 12)
MD Conference Express - ENDO 2015 - Contents (Page 13)
MD Conference Express - ENDO 2015 - Contents (Page 14)
MD Conference Express - ENDO 2015 - Contents (Page 15)
MD Conference Express - ENDO 2015 - Contents (Page 16)
MD Conference Express - ENDO 2015 - Contents (Page 17)
MD Conference Express - ENDO 2015 - Contents (Page 18)
MD Conference Express - ENDO 2015 - Contents (Page 19)
MD Conference Express - ENDO 2015 - Contents (Page 20)
MD Conference Express - ENDO 2015 - Contents (Page 21)
MD Conference Express - ENDO 2015 - Contents (Page 22)
MD Conference Express - ENDO 2015 - Contents (Page 23)
MD Conference Express - ENDO 2015 - Contents (Page 24)
MD Conference Express - ENDO 2015 - Contents (Page 25)
MD Conference Express - ENDO 2015 - Contents (Page 26)
MD Conference Express - ENDO 2015 - Contents (Page Cover3)
MD Conference Express - ENDO 2015 - Contents (Page Cover4)
https://www.nxtbook.com/nxtbooks/md_conference_express/endo2015
https://www.nxtbookmedia.com